Xenon Pharmaceuticals Pauses Depression Trial Enrollment, Sending Shares Down 25%

2 articles · Updated · CNBC · Sep 18

Xenon Pharmaceuticals tumbled 25% in premarket trading after it halted enrollment of new patients in clinical studies for major and bipolar depression treatments.
Neuropsychiatric side effects detected in those studies triggered the pause, which the company said is expected to be temporary.
The move stood out among premarket decliners, with Netflix down more than 3% after a downgrade and steelmakers Steel Dynamics and Nucor each off more than 1.5% on weak guidance.

Sources

Left100%

What specific neuropsychiatric side effects forced Xenon to halt its depression trials, and can the program recover?

Why are investors punishing major steelmakers for earnings misses when their customer backlogs are actually surging?

Could Netflix's shift toward older library content secretly boost its future margins despite the recent analyst downgrade?